|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Agra IM, Ferlito A, Takes RP, Silver CE,
Olsen KD, Stoeckli SJ, Strojan P, Rodrigo JP, Gonçalves Filho J,
Genden EM, et al: Diagnosis and treatment of recurrent laryngeal
cancer following initial nonsurgical therapy. Head Neck.
34:727–735. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marioni G, Marchese-Ragona R, Cartei G,
Marchese F and Staffieri A: Current opinion in diagnosis and
treatment of laryngeal carcinoma. Cancer Treat Rev. 32:504–515.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kahlert C, Lahes S, Radhakrishnan P, Dutta
S, Mogler C, Herpel E, Brand K, Steinert G, Schneider M,
Mollenhauer M, et al: Overexpression of ZEB2 at the invasion front
of colorectal cancer is an independent prognostic marker and
regulates tumor invasion in vitro. Clin Cancer Res. 17:7654–7663.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hanrahan K, O'Neill A, Prencipe M, Bugler
J, Murphy L, Fabre A, Puhr M, Clig Z, Murphy K and Watson RW: The
role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in
mediating docetaxel-resistant prostate cancer. Mol Oncol.
11:251–265. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Galvan JA, Zlobec I, Wartenberg M, Lugli
A, Gloor B, Perren A and Karamitopoulou E: Expression of E-cadherin
repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells
influences tumour-budding phenotype and suggests heterogeneity of
stromal cells in pancreatic cancer. Br J Cancer. 112:1944–1950.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brabletz S and Brabletz T: The ZEB/miR-200
feedback loop-A motor of cellular plasticity in development and
cancer? EMBO Rep. 11:670–677. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li J, Riedt T, Goossens S, Carrillo García
C, Szczepanski S, Brandes M, Pieters T, Dobrosch L, Gütgemann I,
Farla N, et al: The EMT transcription factor Zeb2 controls adult
murine hematopoietic differentiation by regulating cytokine
signaling. Blood. 129:460–472. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sugimoto M, Kohashi K, Itsumi M, Shiota M,
Abe T, Yamada Y, Kuroiwa K, Naito S and Oda Y: Epithelial to
mesenchymal transition in clear cell renal cell carcinoma with
rhabdoid features. Pathobiology. 83:277–286. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cappellesso R, Marioni G, Crescenzi M,
Guzzardo V, Mussato A, Staffieri A, Martini A, Blandamura S and
Fassina A: The prognostic role of the epithelial-mesenchymal
transition markers E-cadherin and slug in laryngeal squamous cell
carcinoma. Histopathology. 67:491–500. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gao S, Wang J, Xie J, Zhang T and Dong P:
Role of miR-138 in the regulation of larynx carcinoma cell
metastases. Tumour Biol. 2015.
|
|
13
|
Chu EA and Kim YJ: Laryngeal cancer:
Diagnosis and preoperative work-up. Otolaryngol Clin North Am.
41:673–695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ashkenazi A and Salvesen G: Regulated cell
death: Signaling and mechanisms. Annu Rev Cell Dev Biol.
30:337–356. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Weidenfeld K and Barkan D: EMT and
stemness in tumor dormancy and outgrowth: Are they intertwined
processes. Front Oncol. 8:3812018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li MZ, Wang JJ, Yang SB, Li WF, Xiao LB,
He YL and Song XM: ZEB2 promotes tumor metastasis and correlates
with poor prognosis of human colorectal cancer. Am J Transl Res.
9:2838–2851. 2017.PubMed/NCBI
|
|
18
|
Lan T, Chang L, Wu L and Yuan Y:
Downregulation of ZEB2-AS1 decreased tumor growth and metastasis in
hepatocellular carcinoma. Mol Med Rep. 14:4606–4612. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Geng DM, Kan XM and Zhang WW: Effect of
ZEB2 silencing on cisplatin resistance in gastric cancer. Eur Rev
Med Pharmacol Sci. 21:1746–1752. 2017.PubMed/NCBI
|
|
20
|
Shay G, Lynch CC and Fingleton B: Moving
targets: Emerging roles for MMPs in cancer progression and
metastasis. Matrix Biol. 44-46:200–206. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chaudhary AK, Pandya S, Ghosh K and
Nadkarni A: Matrix metalloproteinase and its drug targets therapy
in solid and hematological malignancies: An overview. Mutat Res.
753:7–23. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hsieh CY, Tsai PC, Chu CL, Chang FR, Chang
LS, Wu YC and Lin SR: Brazilein suppresses migration and invasion
of MDA-MB-231 breast cancer cells. Chem Biol Interact. 204:105–115.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bieging KT, Mello SS and Attardi LD:
Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev
Cancer. 14:359–370. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Morgan DO: Principles of CDK regulation.
Nature. 374:131–134. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qi S, Song Y, Peng Y, Wang H, Long H, Yu
X, Li Z, Fang L, Wu A, Luo W, et al: ZEB2 mediates multiple
pathways regulating cell proliferation, migration, invasion, and
apoptosis in glioma. PLoS One. 7:e388422012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu R, Yu BX, Chen JF, Lv XY, Yan ZJ, Cheng
Y and Ma Q: Anti-tumor effects of Atractylenolide I on bladder
cancer cells. J Exp Clin Cancer Res. 35:402016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu W, Yang Y, Deng G, Ma L, Wei G, Zheng
G, Han X, He D, Zhao Y, He J, et al: Vernodalol enhances
TRAIL-induced apoptosis in diffuse large B-cell lymphoma cells. Mol
Carcinog. 56:2190–2199. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Singh M, Yelle N, Venugopal C and Singh
SK: EMT: Mechanisms and therapeutic implications. Pharmacol Ther.
182:80–94. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vandewalle C, Comijn J, De Craene B,
Vermassen P, Bruyneel E, Andersen H, Tulchinsky E, Van Roy F and
Berx G: SIP1/ZEB2 induces EMT by repressing genes of different
epithelial cell-cell junctions. Nucleic Acids Res. 33:6566–6578.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Prislei S, Martinelli E, Zannoni GF,
Petrillo M, Filippetti F, Mariani M, Mozzetti S, Raspaglio G,
Scambia G and Ferlini C: Role and prognostic significance of the
epithelial-mesenchymal transition factor ZEB2 in ovarian cancer.
Oncotarget. 6:18966–18979. 2015. View Article : Google Scholar : PubMed/NCBI
|
